This page shows the latest Revlar news and features for those working in and with pharma, biotech and healthcare.
Revlar/Breo and Anoro offset ongoing Seretide decline with new sales growth.
The top-line growth exceeded expectations, but there are lingering concerns about the slow growth of new respiratory drugs Revlar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide), which together
The site in Ware, Hertfordshire, is focused on the manufacture of the Revlar Ellipta inhaler – a device to administer medicines for respiratory conditions, such as asthma.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
No results were found
We create experiences that inspire lasting change. Exceptional experiences that engage people, change mindsets and behaviour, enrich cultures, increase skills...